Research and Markets: PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis: Event-Driven Update

DUBLIN--()--Research and Markets ( has announced the addition of GlobalData's new report "PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis Event-Driven Update" to their offering.

The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Japanese physicians surveyed for this report follow guidelines such as ACR or guidelines from the Japanese Rheumatology Association, but also follow their own clinical experience. However, diagnosis of mild RA in Japan begins with the PCP or other specialists, then progresses to referral to a rheumatologist. Interestingly, in Japan, internists and orthopedic surgeons may be the treating physicians as rheumatology is a rare specialty, though gaining more popularity (Miyasaka, 2011). Also, most people seeking treatment are 35 years and older. Within this age group, female and male distribution is comparable.


- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in Japan from 2011 to 2022.

- Analysis of the impact of key events as well the drivers and restraints affecting the Japan rheumatoid arthritis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in Japan

- Obtain sales forecast from 2011-2022 in the Japan

Product Profiles - Major Brands

- Enbrel (etanercept)

- Humira (adalimumab)

- Remicade (infliximab)

- Simponi (golimumab)

- Cimzia (certolizumab pegol)

- Orencia (abatacept)

- Actemra/RoActemra (tocilizumab)

- Rituxan/MabThera (rituximab)

- Methotrexate Sodium (numerous generic names)


For more information visit

Source: GlobalData


Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders


Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders